drugset / Trial / NCT02875002
Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
Phase 1
Withdrawn
Yale University
Massey Cancer Center · collabSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase 1, multicenter, open-label study is designed to find the RP2D of volasertib, a PLK1 inhibitor, and belinostat, an HDAC inhibitor, when given in combination to patients with relapsed or refractory B-cell or T-cell lymphoma. A standard 3+3 dose-escalation design will be employed with study enrollment beginning at dose level 1.
Timeline
- Start
- 2016-10
- Primary completion
- 2018-03
- Completion
- 2018-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belinostat | Small molecule | 600 mg/m2 | Other |
| Subject | Belinostat | Small molecule | 1000 mg/m2 | Other |
| Subject | Volasertib | Small molecule | 25 mg/m2 | Other |
| Subject | Volasertib | Small molecule | 100 mg/m2 | Other |